These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8998191)

  • 1. Circulating prostate-specific antigen/CD14-double-positive cells: a biomarker indicating low risk for hematogeneous metastasis of prostate cancer.
    Brandt B; Griwatz C; Brinkmann O; Zänker KS
    J Natl Cancer Inst; 1997 Jan; 89(2):174. PubMed ID: 8998191
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prostate cancer screening with a new marker based on circulating blood macrophages?].
    Herwig R; Djavan B; Kramer G; El-Taieb MA; Kühhas F; Leers M; Marberger M
    Urologe A; 2007 Sep; 46(9):1066-70. PubMed ID: 17622505
    [No Abstract]   [Full Text] [Related]  

  • 3. [From antigen to tumor marker. Results of research regarding PSA and its clinical applications].
    De Angelis G; Brandt B; Schmid HP; Semjonow A
    Urologe A; 2000 Jul; 39(4):309-12. PubMed ID: 10957771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
    Eisenberger MA; Nelson WG
    J Natl Cancer Inst; 1996 Jun; 88(12):779-81. PubMed ID: 8637038
    [No Abstract]   [Full Text] [Related]  

  • 5. Surrogate end points for prostate cancer: what is prostate-specific antigen telling us?
    Sandler HM; DeSilvio ML
    J Natl Cancer Inst; 2003 Sep; 95(18):1352-3. PubMed ID: 13130102
    [No Abstract]   [Full Text] [Related]  

  • 6. Prostate cancer and prostate-specific antigen: the more we know, the less we understand.
    Thompson I; Leach RJ; Pollock BH; Naylor SL
    J Natl Cancer Inst; 2003 Jul; 95(14):1027-8. PubMed ID: 12865440
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
    Loeb S; Metter EJ; Carter HB
    J Natl Cancer Inst; 2011 Nov; 103(21):1636-7; author reply 1637. PubMed ID: 21926375
    [No Abstract]   [Full Text] [Related]  

  • 8. [PSA 2010--the beginning of a new era in early detection of prostate cancer].
    Börgermann C; Sieverding M; Fornara P; Graefen M; Hammerer P; Semjonow A; Schröder F; Rübben H
    Urologe A; 2006 Sep; 45 Suppl 4():127-33. PubMed ID: 16941115
    [No Abstract]   [Full Text] [Related]  

  • 9. Will emerging prostate cancer markers redeem themselves?
    Hotakainen K; Stenman UH
    Clin Chem; 2010 Aug; 56(8):1212-3. PubMed ID: 20570933
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical value of total and free prostatic specific antigen in prostatic cancer].
    Liubimova NV; Kushlinskiĭ NE; Stogova EV; Bronnikov IIu; Gorilovskiĭ LM
    Klin Lab Diagn; 1998 Feb; (2):6-9. PubMed ID: 9553336
    [No Abstract]   [Full Text] [Related]  

  • 11. Improved biomarkers for prostate cancer: a definite need.
    Carter HB; Isaacs WB
    J Natl Cancer Inst; 2004 Jun; 96(11):813-5. PubMed ID: 15173257
    [No Abstract]   [Full Text] [Related]  

  • 12. The Risk of Distant Metastases and Cancer Specific Survival in Men with Serum Prostate Specific Antigen Values above 100 ng/ml.
    Stattin K; Sandin F; Bratt O; Lambe M
    J Urol; 2015 Dec; 194(6):1594-600. PubMed ID: 26192253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
    Schriefer P; Steurer S; Huland H; Graefen M
    J Clin Oncol; 2012 Nov; 30(32):e341-4. PubMed ID: 23032622
    [No Abstract]   [Full Text] [Related]  

  • 14. PSA and the detection of prostate cancer.
    Robbins AS
    JAMA; 1994 Jan; 271(3):192-3. PubMed ID: 7506314
    [No Abstract]   [Full Text] [Related]  

  • 15. [Significance of the PSA-concentration for the detection of prostate cancer].
    Stachon A
    Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of different prostate-specific antigen-based markers in men with baseline total prostate-specific antigen <2.0 ng/mL.
    Fujizuka Y; Ito K; Oki R; Suzuki R; Sekine Y; Koike H; Matsui H; Shibata Y; Suzuki K
    Int J Urol; 2017 Aug; 24(8):602-609. PubMed ID: 28560739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosing prostate cancer: getting to the core question.
    Hernandez DJ
    J Urol; 2013 Jul; 190(1):11-2. PubMed ID: 23608039
    [No Abstract]   [Full Text] [Related]  

  • 18. The time is ripe to redefine high-risk prostate cancer?
    Lim SK; Rha KH
    BJU Int; 2014 Feb; 113(2):181. PubMed ID: 24712698
    [No Abstract]   [Full Text] [Related]  

  • 19. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens.
    Shibata A
    Cancer; 1999 Mar; 85(5):1208-10. PubMed ID: 10091812
    [No Abstract]   [Full Text] [Related]  

  • 20. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
    Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
    Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.